These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 19674978)

  • 1. A new subtype of frontotemporal lobar degeneration with FUS pathology.
    Neumann M; Rademakers R; Roeber S; Baker M; Kretzschmar HA; Mackenzie IR
    Brain; 2009 Nov; 132(Pt 11):2922-31. PubMed ID: 19674978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene.
    Snowden JS; Hu Q; Rollinson S; Halliwell N; Robinson A; Davidson YS; Momeni P; Baborie A; Griffiths TD; Jaros E; Perry RH; Richardson A; Pickering-Brown SM; Neary D; Mann DM
    Acta Neuropathol; 2011 Jul; 122(1):99-110. PubMed ID: 21424531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations.
    Neumann M; Bentmann E; Dormann D; Jawaid A; DeJesus-Hernandez M; Ansorge O; Roeber S; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ang LC; Bilbao J; Rademakers R; Haass C; Mackenzie IR
    Brain; 2011 Sep; 134(Pt 9):2595-609. PubMed ID: 21856723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expanding the Phenotype of Frontotemporal Lobar Degeneration With FUS-Positive Pathology (FTLD-FUS).
    Chornenka K; Hirsch-Reinshagen V; Perez-Rosendahl M; Feldman H; Segal-Gidan F; Vinters HV; Mackenzie IR
    J Neuropathol Exp Neurol; 2020 Jul; 79(7):809-812. PubMed ID: 32483606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies.
    Lashley T; Rohrer JD; Bandopadhyay R; Fry C; Ahmed Z; Isaacs AM; Brelstaff JH; Borroni B; Warren JD; Troakes C; King A; Al-Saraj S; Newcombe J; Quinn N; Ostergaard K; Schrøder HD; Bojsen-Møller M; Braendgaard H; Fox NC; Rossor MN; Lees AJ; Holton JL; Revesz T
    Brain; 2011 Sep; 134(Pt 9):2548-64. PubMed ID: 21752791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis.
    Verbeeck C; Deng Q; Dejesus-Hernandez M; Taylor G; Ceballos-Diaz C; Kocerha J; Golde T; Das P; Rademakers R; Dickson DW; Kukar T
    Mol Neurodegener; 2012 Oct; 7():53. PubMed ID: 23046583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of ubiquitin and FUS-positive, TDP-43-negative frontotemporal lobar degeneration.
    Seelaar H; Klijnsma KY; de Koning I; van der Lugt A; Chiu WZ; Azmani A; Rozemuller AJ; van Swieten JC
    J Neurol; 2010 May; 257(5):747-53. PubMed ID: 19946779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FUS pathology in basophilic inclusion body disease.
    Munoz DG; Neumann M; Kusaka H; Yokota O; Ishihara K; Terada S; Kuroda S; Mackenzie IR
    Acta Neuropathol; 2009 Nov; 118(5):617-27. PubMed ID: 19830439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct pathological subtypes of FTLD-FUS.
    Mackenzie IR; Munoz DG; Kusaka H; Yokota O; Ishihara K; Roeber S; Kretzschmar HA; Cairns NJ; Neumann M
    Acta Neuropathol; 2011 Feb; 121(2):207-18. PubMed ID: 21052700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration.
    Urwin H; Josephs KA; Rohrer JD; Mackenzie IR; Neumann M; Authier A; Seelaar H; Van Swieten JC; Brown JM; Johannsen P; Nielsen JE; Holm IE; ; Dickson DW; Rademakers R; Graff-Radford NR; Parisi JE; Petersen RC; Hatanpaa KJ; White CL; Weiner MF; Geser F; Van Deerlin VM; Trojanowski JQ; Miller BL; Seeley WW; van der Zee J; Kumar-Singh S; Engelborghs S; De Deyn PP; Van Broeckhoven C; Bigio EH; Deng HX; Halliday GM; Kril JJ; Munoz DG; Mann DM; Pickering-Brown SM; Doodeman V; Adamson G; Ghazi-Noori S; Fisher EM; Holton JL; Revesz T; Rossor MN; Collinge J; Mead S; Isaacs AM
    Acta Neuropathol; 2010 Jul; 120(1):33-41. PubMed ID: 20490813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel types of frontotemporal lobar degeneration: beyond tau and TDP-43.
    Mackenzie IR; Neumann M; Cairns NJ; Munoz DG; Isaacs AM
    J Mol Neurosci; 2011 Nov; 45(3):402-8. PubMed ID: 21603977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological features of FTLD-FUS in a Japanese population: analyses of nine cases.
    Kobayashi Z; Kawakami I; Arai T; Yokota O; Tsuchiya K; Kondo H; Shimomura Y; Haga C; Aoki N; Hasegawa M; Hosokawa M; Oshima K; Niizato K; Ishizu H; Terada S; Onaya M; Ikeda M; Oyanagi K; Nakano I; Murayama S; Akiyama H; Mizusawa H
    J Neurol Sci; 2013 Dec; 335(1-2):89-95. PubMed ID: 24050818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frontotemporal lobar degeneration and amyotrophic lateral sclerosis: molecular similarities and differences.
    Neumann M
    Rev Neurol (Paris); 2013 Oct; 169(10):793-8. PubMed ID: 24011641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An autopsied case of sporadic adult-onset amyotrophic lateral sclerosis with FUS-positive basophilic inclusions.
    Matsuoka T; Fujii N; Kondo A; Iwaki A; Hokonohara T; Honda H; Sasaki K; Suzuki SO; Iwaki T
    Neuropathology; 2011 Feb; 31(1):71-6. PubMed ID: 20573033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topography of FUS pathology distinguishes late-onset BIBD from aFTLD-U.
    Lee EB; Russ J; Jung H; Elman LB; Chahine LM; Kremens D; Miller BL; Branch Coslett H; Trojanowski JQ; Van Deerlin VM; McCluskey LF
    Acta Neuropathol Commun; 2013 May; 1(9):1-11. PubMed ID: 24027631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TDP-43 and FUS/TLS: cellular functions and implications for neurodegeneration.
    Fiesel FC; Kahle PJ
    FEBS J; 2011 Oct; 278(19):3550-68. PubMed ID: 21777389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management.
    Seltman RE; Matthews BR
    CNS Drugs; 2012 Oct; 26(10):841-70. PubMed ID: 22950490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuronal intermediate filament inclusion disease may be incorrectly classified as a subtype of FTLD-FUS.
    Bieniek KF; Josephs KA; Lin WL; Dickson DW
    Free Neuropathol; 2020; 1():. PubMed ID: 34386806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frontotemporal lobar degeneration: Pathogenesis, pathology and pathways to phenotype.
    Mann DMA; Snowden JS
    Brain Pathol; 2017 Nov; 27(6):723-736. PubMed ID: 28100023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments.
    Swarup V; Phaneuf D; Bareil C; Robertson J; Rouleau GA; Kriz J; Julien JP
    Brain; 2011 Sep; 134(Pt 9):2610-26. PubMed ID: 21752789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.